Here s where you can see a rocket launch in the U S nationalgeographic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationalgeographic.com Daily Mail and Mail on Sunday newspapers.
(2)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the first CellFX
procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210219005136/en/
Press release content from Business Wire. The AP news staff was not involved in its creation.
Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch
February 19, 2021 GMT
HAYWARD, Calif. (BUSINESS WIRE) Feb 19, 2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX ® procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company’s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company’s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.
Published: Feb 16, 2021
Pulse Biosciences Announces Start of Controlled Launch of the CellFX System
®
- First Aesthetic Dermatology Patients Treated in the U.S.
HAYWARD, Calif. (BUSINESS WIRE) Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first clinic patients have been treated with the CellFX
® System. This first commercial use of the CellFX System marks the initiation of the Company’s controlled launch program with product shipments to respected leaders in dermatology in the U.S. and in Europe.
The CellFX System for cellular-based skin conditions (Photo: Pulse Biosciences)